Table 2.

Final adjusted longitudinal model* estimates for tumor necrosis factor-α (TNF-α) inhibitor use status. Values are median (interquartile range).

Total on TNF-α Inhibitors
AllNo StatinsNo Statins or Diabetes
Total cholesterol (TC)1.55 (−2.93, 6.04)3.45 (−3.17, 10.07)0.33 (−6.93, 7.59)
HDL0.42 (−0.94, 1.78)1.48 (−0.75, 3.70)1.47 (−1.17, 4.10)
LDL−1.73 (−5.52, 1.99)−2.18 (−7.52, 3.16)−0.62 (−6.67, 5.43)
Triglyceride9.11 (−1.56, 19.77)13.31 (−2.45, 29.08)2.43 (−13.77, 18.62)
TC/HDL0.004 (−0.12, 0.13)−0.01 (−0.19, 0.16)−0.06 (−0.26, 0.14)
LDL/HDL−0.03 (−0.12, 0.07)−0.05 (−0.18, 0.08)−0.05 (−0.20, 0.10)
  • * Adjusted for sex, age at RA diagnosis, race, body mass index (time-varying), rheumatoid factor (yes/no), diabetes, hypertension, and use (time-varying) of steroids, nonsteroidal antiinflammatory drugs, methotrexate, hydroxychloroquine, statins (classified as none, low, medium, high potency), and other lipid-lowering medications. HDL: high-density lipoprotein; LDL: low-density lipoprotein.